Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Only the indication/brand and IOP-lowering claims are supported by the provided FDA label excerpts. Several additional claims (common redness/irritation and counterfeit/non-traceable supply risk) are not supported by the supplied label text, and key label safety/dosing sections are not addressed.
Category Scores
Accurate Statements
Rhopressa is the brand name of netarsudil ophthalmic solution.
Supported by label section 11 (DESCRIPTION) identifying RHOPRESSA (netarsudil ophthalmic solution) 0.02%.
Netarsudil ophthalmic solution is used for glaucoma.
Supported by label section 1 (INDICATIONS AND USAGE): reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.
Netarsudil ophthalmic solution is used for ocular hypertension.
Supported by label section 1 (INDICATIONS AND USAGE).
Rhopressa (netarsudil) is used to help lower intraocular pressure.
Supported by label section 1 (INDICATIONS AND USAGE): indicated for reduction of elevated IOP.
Unsupported Statements
With netarsudil ophthalmic products, patients commonly report redness of the eye.
The provided label excerpts do not include adverse reaction frequency information supporting 'commonly report redness of the eye.'
With netarsudil ophthalmic products, patients commonly report irritation.
The provided label excerpts do not include adverse reaction frequency information supporting 'commonly report irritation.'
If a product listing is not from a legitimate source, there is a risk of non-traceable supply, including counterfeit or wrong strength/formulation.
No provided FDA label excerpt supports this statement.
Contradictions
Important Omissions
Dosage and administration details (e.g., dosing regimen) and related label context were not provided.
Importance:
Moderate
Safety-critical label content (e.g., warnings/precautions, adverse reactions details, contraindications, and use in specific populations) was not addressed in the evaluated response.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The response includes unsupported safety-related claims (common redness/irritation) and omits key safety-critical labeling elements (within the provided label sections framework, such as warnings/precautions and adverse reaction details). While it does not directly provide unsafe dosing, the missing label safety context and unsupported assertions reduce labeling fidelity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the supplied FDA label excerpts (common redness/irritation; counterfeit/non-traceable supply risk), and key label safety/dosing sections are omitted.
Suggested Improvement
Limit statements to the provided label-supported indication/IOP-lowering claims and omit or re-quote adverse reaction frequency and supply-source/counterfeit statements unless supported by the actual FDA label text; include relevant dosage/admin and safety/contraindication elements from the label when answering labeling-adherence questions.